RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats

Journal of Bone and Mineral Research

Volumn 23, Issue 5, 2008, Pages 672-682

  Ominsky, Michael S ^a   Li, Xiaodong ^a   Asuncion, Frank J ^a   Barrero, Mauricio ^a   Warmington, Kelly S ^a   Dwyer, Denise ^a   Stolina, Marina ^a   Geng, Zhaopo ^a   Grisanti, Mario ^a   Tan, Hong Lin ^a   Corbin, Timothy ^a   McCabe, James ^a   Simonet, William S ^a   Ke, Hua Z ^a   Kostenuik, Paul J ^a,b  

^a AMGEN INC   (United States)

^b M/S 15 2 B ^*  (United States)

Author keywords

Bone strength; Cortical bone; Osteoprotegerin; Ovariectomy; RANKL

Indexed keywords

BIOCHEMICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN TRACP5B; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; CELL SURFACE; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; FEMUR NECK; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PROTEIN BLOOD LEVEL; RAT; THICKNESS; TRABECULAR BONE; WEIGHT BEARING;

ANIMALS; BONE AND BONES; FEMALE; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42449146580     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080109     Document Type: Article

References (45)

1. Burgess T, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan C, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448.
4. Hsu H, Lacey DL, Dunstan C, Solovyev I, Colombero A, Timms E, Tan HL, Elliot G, Kelley MJ, Sarosi I, Wang L, Xia X, Elliot R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
5. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Malisczewski CR, Armstron A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424.
6. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliot R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik PJ, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
7. Simonet WS, Lacey DL, Dunstan C, Kelly M, Chang MS, Luthy R, Nhuyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
8. Tsuda E, Goto M, Mochizuki SI, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142.
9. Raisz LG 2005 Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115:3318-3325.
10. Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM 2001 The ratio of messenger RNA levels of receptor activator of nuclear factor κB ligand to osteoprotegerin correlates with bone remodeling in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015-1027.
11. Geusens PP, Landewe R, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde D, van der Linden S, Boers M 2006 The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772-1777.
12. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D 2003 Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163:2021-2031.
13. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370.
14. Saika M, Inoue D, Kido S, Matsumoto T 2001 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142:2205-2212.
15. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM 2002 Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550-1554.
16. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230.
17. Miyazaki T, Matsunaga T, Miyazaki S, Hokari S, Komada T 2004 Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J Cell Biochem 93:503-512.
18. Ikeda T, Utsuyama M, Hirokawa K 2001 Expression profiles of receptor activator of nuclear factor κB ligand, receptor activator of nuclear factor κB, and osteoprotegerin messenger mRAN in aged ovariectomized rat bones. J Bone Miner Res 16:1416-1425.
19. Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Tamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, Takahashi N 2007 Osteoprotegerin reduces the serum level of receptor activator of NF-κ ligand derived from osteoblasts. J Immunol 178:192-200.
20. Yoneda T, Ishimaru N, Arakaki R, Kobayashi M, Izawa T, Moriyama K, Hayashi Y 2004 Estrogen deficiency accelerates murine autoimmune arthritis asociated with receptor activator of nuclear factor-κ B ligand-mediated osteoclastogenesis. Endocrinology 145:2384-2391.
21. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4305.
22. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63.
23. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831.
24. Kamel HK, Hussain MS, Tariq S, Perry HM, Morley JE 2000 Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 109:326-328.
25. Ross AB, Bateman TA, Kostenuik PJ, Ferguson VL, Lacey DL, Dunstan CR, Simske SJ 2001 The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 12:583-588.
26. Qiu S, Rao DS, Palnitkar S, Parfitt AM 2006 Independent and combined contributions of cancellous and cortical bone deficits to vertebral fracture risk in postmenopausal women. J Bone Miner Res 21:1791-1796.
27. Sornet-Rendu E, Boutroy S, Munoz F, Delmas PD 2007 Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA. J Bone Miner Res 22:425-433.
28. Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, San Martin J 2007 Severity of vertebral fracture reflects deterioration of bone micoarchitecture. Osteoporos Int 18:69-79.
29. Augat P, Reeb H, Claes LE 1996 Prediction of fracture load at different skeletal sites by geometric properties of the cortical shell. J Bone Miner Res 11:1356-1363.
30. Eswaran SK, Gupta A, Adams MF, Keaveny TM 2005 Role of cortical shell in vertebral strength assessment. J Bone Miner Res 20:S66.
31. Follet H, Boivin GY, Rumelhart C, Meunier PJ 2004 The degree of mineralization is a determinant of bone strength: A study on human calcanei. Bone 34:783-789.
32. Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer K 2005 Combined treatment with PTH-(1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 37:87-95.
33. Stolina M, Adamu S, Ominsky MS, Dzamba BJ, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ 2005 RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756-1765.
34. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
35. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449.
36. Vesterby A, Mosekilde Li, Gundersen H, Melsen F, Mosekilde Le, Holme K, Sorensen S 1991 Biologically meaningful determinants of the in vitro strength of lumbar vertebrae. Bone 12:219-224.
37. Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A, Sato M 2007 Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. J Bone Miner Res 22:841-848.
38. Atkinson J, Cranmer P, Saunders T, Niehaus M, Smith SY, Varela A, Ominsky MS, Cosenza ME, Kostenuik PJ 2005 AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 20:S294.
39. van der Linden JC, Homminga J, Verhaar J, Weinans H 2001 Mechanical consequences of bone loss in cancellous bone. J Bone Miner Res 16:457-465.
40. Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portrero NR, Meunier PJ 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97-103.
41. Hildebrand T, Ruegsegger P 1997 Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1:15-23.
42. 3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88:4199-4205.
43. Boivin GY, Vedi S, Purdie DW, Compston JE, Meunier PJ 2005 Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: A quantitative microradiographic analysis in postmenopausal women. Bone 36:562-567.
44. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
45. Erben RG 1996 Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling? Anat Rec 246:39-46.